OCT & Retina Forum 2022
Integrating the new available technologies into the clinical practice of vitreoretinal diseases
OCT & Retina Forum 2022
Integrating the new available technologies into the clinical practice of vitreoretinal diseases
Among the main topics of the 2022 edition of the OCT & RETINA Forum is the integration of new technologies with the treatments available in clinical practice, not only for research purposes but mainly because they are crucial for the diagnosis of retinal diseases and therapy. The congress program includes presentations on imaging, focus on therapies, updates on the treatments of maculopathies, of vascular and retinal diseases. Some of the most important researchers present the results of the latest trials.
Among the main topics of the 2022 edition of the OCT & RETINA Forum is the integration of new technologies with the treatments available in clinical practice, not only for research purposes but mainly because they are crucial for the diagnosis of retinal diseases and therapy. The congress program includes presentations on imaging, focus on therapies, updates on the treatments of maculopathies, of vascular and retinal diseases. Some of the most important researchers present the results of the latest trials.
interviews
Neovascular AMD after 10 years of treatment
it
Prof. Giovanni Staurenghi
AMD, therapeutic novelties for the dry form
it
Prof. Alfonso Giovannini
Structure and advancement of the DRCR network
en
Lee M. Jampol, MD
Ophtalmic clinical and reaserch activities are resuming vigorously
it
Dott. Alfredo Pece
AMD, longer intervals between treatments with new anti VEGF
it
Dr. Riccardo Sacconi
From collagen alterations to early keratoconus diagnosis
it
Dr. Luisa Pierro
Brolucizumab in naive patients with occult neovascular AMD
it
Dr. Lisa Toto
The brolucizumab treatment regimen in naive patients
it
Dr. Maria Oliva Grassi
